Tianjin Med J ›› 2016, Vol. 44 ›› Issue (2): 213-217.doi: 10.11958/59060

Previous Articles     Next Articles

Analysis of curative effect of the NB09 protocol based on 95 children with stage 4 neuroblastomas

ZHONG Benfu, ZHAO Qiang△, YAN Jie, WANG Jingfu, LI Zhanglin, CAO Yanna, LI Jie, LI Zhongyuan, WANG Huijuan   

  1. Department of Pediatric Oncology, Tianjin Medical University Cancer Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China
  • Received:2015-06-08 Revised:2015-10-13 Published:2016-02-15 Online:2016-02-15
  • Contact: △Corresponding Author E-mail: qiangzhao169@aliyun.com E-mail:qiangzhao169@yahoo.com.cn

Abstract: Objective To assess the outcomes of stage 4 neuroblastomas (NB), and analyze the associated prognostic factors. Methods Ninety-five children with stage 4 NB were retrospectively analyzed. The curative effects and related factors affecting prognosis were compared between NB09 protocol group (n=40) and non-NB09 group (n=55). The median age of 95 children was 48 months (4-136 months), and the median follow-up time was 21 months (4-179 months). Results The total survival rate and progression free survival rate were significantly better in NB09 group than those of non-NB09 group (χ2=6.916 and 0.025, P<0.05). The univariate analysis showed that treatment plan, pathologival type, bone marrow involvement>20%, N-MYC amplification, surgical extent<90%, non-therapy of cis-retinoic acid, LDH>1 000 U/L and very good partial remission (VGPR) were the influencing factors for the prognosis in children (P<0.05). Multivariate regression analy⁃ sis showed that bone marrow involvement>20% was the bad independent prognostic factors for stage 4 patients. Conclusion Children with stage 4 NB treated according to the NB09 protocol have a better prognosis. Children of stage 4 neuro⁃ blastomas with bone marrow involvement >20% have a bad prognosis to current treatment.

Key words: neuroblastoma, therapy, prognosis, child, NB09 protocol